SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Supplementary materials for the publication of Strober B. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol 2022.
创建时间：
2022-10-26
